Compare · ARGX vs REGN
ARGX vs REGN
Side-by-side comparison of argenx SE (ARGX) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ARGX focuses on Biotechnology: Biological Products (No Diagnostic Substances), while REGN focuses on Biotechnology: Pharmaceutical Preparations.
- REGN is the larger of the two at $95.52B, about 1.6x ARGX ($58.47B).
- REGN has been more active in the news (26 items in the past 4 weeks vs 6 for ARGX).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Regeneron Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $58.47B
- $95.52B
- 1M return
- +6.26%
- -
- 1Y return
- +2.78%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 1991
- News (4w)
- 6
- 26
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
- Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
- Amendment: SEC Form SCHEDULE 13G/A filed by argenx SE
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
- argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
- SEC Form 6-K filed by argenx SE
Latest REGN
- SEC Form S-8 filed by Regeneron Pharmaceuticals Inc.
- FDA Approval for LIVSAYIS issued to REGENERON PHARMACEUTICALS
- Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)
- Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
- Director George L Sing sold $1,917,945 worth of shares (2,000 units at $958.97), decreasing direct ownership by 8% to 23,147 units (SEC Form 4)
- EVP Commercial Marion Mccourt sold $543,504 worth of shares (566 units at $960.25) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 10,305 units (SEC Form 4)
- Co-Chief Scientific Officer Andrew J Murphy exercised 17,000 shares at a strike of $381.92, covered exercise/tax liability with 11,989 shares and sold $4,799,336 worth of shares (5,011 units at $957.76) as part of a pre-agreed trading plan (SEC Form 4)
- Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer Indications
- POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms
- CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD